



**BAL PHARMA LIMITED**  
**Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099**  
**UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30.09.2012**

(Rs.in Lakhs)

Sr. No:	Particulars	Quarter			Half Year		Year ended 31.03.2012 (Audited)
		30.09.2012 (Unaudited)	30.06.2012 (Unaudited)	30.09.2011 (Unaudited)	30.09.2012 (Unaudited)	30.09.2011 (Unaudited)	
1	Net Sales/Income from operations (Net of Excise Duty)	3,875.86	2,952.30	3,414.15	6,828.16	6,212.37	13,648.98
	Other Operating Income	98.69	46.60	51.79	145.29	86.67	319.68
	<b>Net Income from Sales/Services</b>	<b>3,974.55</b>	<b>2,998.90</b>	<b>3,465.94</b>	<b>6,973.45</b>	<b>6,299.04</b>	<b>13,968.66</b>
2	Expenditure						
	a) Increase/decrease in stock in trade and WIP	246.58	(254.20)	(108.51)	(7.62)	(191.37)	120.28
	b) Consumption of Raw Materials/ Packing Material	1,934.17	1,656.48	1,913.25	3,590.65	3,420.89	7,184.63
	c) Purchase of Stock in Trade	109.82	55.92	101.79	165.74	188.27	375.24
	d) Employee Cost	584.18	585.59	554.47	1,169.77	1,056.45	2,115.41
	e) Depreciation and amortisation expenses	99.78	95.65	90.78	195.43	173.38	413.08
	f) Other Expenditure	684.27	655.95	663.87	1,340.22	1,215.13	2,692.41
	g) Total	<b>3,658.80</b>	<b>2,795.39</b>	<b>3,215.65</b>	<b>6,454.19</b>	<b>5,862.74</b>	<b>12,901.05</b>
3	Profit from Operations before other Income, interest and Exceptional items(1-2)	<b>315.75</b>	<b>203.51</b>	<b>250.30</b>	<b>519.26</b>	<b>436.30</b>	<b>1,067.61</b>
4	Other Non-operating Income	12.78	10.36	14.15	23.14	24.85	107.81
5	Profit before Interest and Exceptional items (3+4)	<b>328.53</b>	<b>213.87</b>	<b>264.44</b>	<b>542.40</b>	<b>461.15</b>	<b>1,175.42</b>
6	Finance Costs	216.83	188.34	175.41	405.17	348.74	729.91
7	Profit after Interest but before Exceptional items	111.70	25.53	89.03	137.23	112.40	445.51
8	Exceptional items	-	-	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax ( 7-8)	111.70	25.53	89.03	137.23	112.40	445.51
10	Tax expenses	18.90	6.32	25.00	25.22	35.00	69.82
11	Net Profit /Loss from ordinary Activities after Tax	92.80	19.21	64.03	112.01	77.40	375.69
12	Extra ordinary items	-	-	-	-	-	-
13	Net Profit / Loss for the period	92.80	19.21	64.03	112.01	77.40	375.69
14	Paid-up Equity Share capital( face value of Rs 10 each )	1,057.36	1,057.36	1,057.36	1,057.36	1,057.36	1,057.36
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	2,948.22	2,948.22	2,601.41	2,948.22	2,601.41	2,601.41
16	<b>EPS ( in Rs. )</b>						
	a) Basic	<b>0.88</b>	<b>0.18</b>	<b>0.61</b>	<b>1.06</b>	<b>0.73</b>	<b>3.57</b>
	b) Diluted	<b>0.88</b>	<b>0.18</b>	<b>0.62</b>	<b>1.06</b>	<b>0.75</b>	<b>3.57</b>
17	<b>Public shareholding</b>						
	- Number of Shares	5,142,086	5,142,086	5,112,086	5,142,086	5,112,086	5,132,086
	- Percentage of shareholding	48.63	48.63	48.32	48.63	48.32	48.53
18	<b>Promoters &amp; Promoter group Shareholding</b>						
	<b>a) Pledged / Encumbered</b>						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shareholding	-	-	-	-	-	-
	<b>b) Non-encumbered</b>						
	- Number of Shares	5,431,538	5,431,538	5,461,538	5,431,538	5,461,538	5,441,538
	- Percentage of shareholding	51.37	51.37	51.68	51.37	51.68	51.47

1 The statement of assets and liabilities as at 30.09.2012 are as follows;

(Rs.in Lakhs)

<b>Particulars</b>	<b>30.09.2012</b>	<b>31.03.2012</b>
Share Capital	1,057.36	1,057.36
Reserves & Surplus	3,060.21	2,948.22
	<b>4,117.58</b>	<b>4,005.58</b>
<b>Non Current Liabilities</b>		
Long-term borrowings	445.71	609.09
Deferred tax liabilities (Net)	766.99	741.77
Other long term liabilities	62.22	63.72
Long-term provisions	63.89	64.37
	<b>1,338.81</b>	<b>1,478.95</b>
<b>Current liabilities</b>		
Short- term borrowings	4,314.59	4,452.94
Trade payables	2,178.49	2,692.17
Other current liabilities	2,165.64	1,395.66
Short- term provisions	121.42	91.08
	<b>8,780.14</b>	<b>8,631.85</b>
<b>TOTAL</b>	<b>14,236.53</b>	<b>14,116.38</b>
<b>Non- current assets</b>		
Fixed Assets	5,333.06	5,330.99
Non- current investments	1.50	1.50
Long term loans and advances	354.36	318.26
Other non-current assets	-	15.93
	<b>5,688.92</b>	<b>5,666.67</b>
<b>Current assets</b>		
Inventories	3,347.22	3,365.95
Trade receivables	4,085.72	3,818.58
Cash and cash equivalents	342.48	302.67
Short-term loans and advances	736.59	931.34
Other current assets	35.60	31.16
	<b>8,547.61</b>	<b>8,449.70</b>
<b>TOTAL</b>	<b>14,236.53</b>	<b>14,116.38</b>

- 1 The above Un-Audited financial results as reviewed by the Audit Committee were approved by the Board of Directors at their meeting held on 09.11.2012.
- 2 Statutory Auditors of the Company has conducted a limited review on the Un-Audited financial results for the quarter ended 30.09.2012.
- 3 Your Company has successfully concluded the preferential allotment of 22,98,748 warrants on 19th October 2012, to the promoters and strategic investors, with each warrant priced at Rs 21/-.
- 4 Investor grievances: Outstanding at the beginning of the quarter : Nil , received during the quarter:4,resolved during the quarter 4, pending at the end of the quarter: Nil.
- 5 Previous year figures were regrouped / rearranged wherever required.
- 6 As the Company deals with a single product i.e Pharmaceuticals, segment wise figures are not furnished.

Bangalore  
9th November 2012

By order of the Board of Directors  
For Bal Pharma limited

Shailesh Siroya  
Managing Director